US20100137358A1
(en)
*
|
1996-11-05 |
2010-06-03 |
Dr. Reddy's Laboratories Ltd. |
Solifenacin compositions
|
WO2008128028A2
(en)
*
|
2007-04-11 |
2008-10-23 |
Dr. Reddy's Laboratories Ltd. |
Solifenacin compositions
|
FR2772378B1
(fr)
*
|
1997-12-12 |
2000-02-04 |
Synthelabo |
Derives d'imidazole, leur preparation et leur application en therapeutique
|
ES2165768B1
(es)
|
1999-07-14 |
2003-04-01 |
Almirall Prodesfarma Sa |
Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
|
US7214687B2
(en)
|
1999-07-14 |
2007-05-08 |
Almirall Ag |
Quinuclidine derivatives and medicinal compositions containing the same
|
JP2001316670A
(ja)
*
|
2000-05-02 |
2001-11-16 |
Dainippon Ink & Chem Inc |
液晶組成物
|
TR200400420T4
(tr)
*
|
2000-06-27 |
2004-03-22 |
Laboratorios S.A.L.V.A.T., S.A. |
Arilalkilaminlerden türetilmiş karbamatlar.
|
PE20020719A1
(es)
*
|
2000-12-22 |
2002-10-11 |
Almirall Prodesfarma Ag |
Derivados de carbamato de quinuclidina como agentes antimuscarinicos m3
|
AU2002238471B2
(en)
|
2000-12-28 |
2007-06-28 |
Almirall, S.A. |
Quinuclidine derivatives and their use as M3 antagonists
|
WO2003006019A1
(fr)
*
|
2001-07-10 |
2003-01-23 |
Yamanouchi Pharmaceutical Co., Ltd. |
Composition medicinale destinee au traitement de la cystite interstitielle
|
KR100944580B1
(ko)
*
|
2001-12-20 |
2010-02-25 |
치에시 파마슈티시 에스.피.아. |
1-알킬-1-아조니아비시클로[2.2.2]옥탄 카르바메이트유도체 및 이의 무스카린 수용체 길항제로서의 용도
|
IL165370A0
(en)
*
|
2002-06-07 |
2006-01-15 |
Astellas Pharma Inc |
Therapeutic agent for overactive bladder
|
ES2203327B1
(es)
|
2002-06-21 |
2005-06-16 |
Almirall Prodesfarma, S.A. |
Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
|
ES2204295B1
(es)
|
2002-07-02 |
2005-08-01 |
Almirall Prodesfarma, S.A. |
Nuevos derivados de quinuclidina-amida.
|
MXPA05000434A
(es)
|
2002-07-08 |
2005-04-19 |
Ranbaxy Lab Ltd |
Derivados de hexano [3.1.0] azabiciclo 3,6-disustituido utiles como antagonistas de receptor muscarinico.
|
WO2004014853A1
(en)
|
2002-07-31 |
2004-02-19 |
Ranbaxy Laboratories Limited |
3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
|
EP1545508A4
(en)
|
2002-08-09 |
2009-11-25 |
Ranbaxy Lab Ltd |
3,6-DISUBSTITUTED AZABICYCLO ¬3.1.0 HEXANE DERIVATIVES AS USEFUL AS MUSCARINIC RECEPTOR AGONISTS
|
EP1534675B1
(en)
|
2002-08-23 |
2009-02-25 |
Ranbaxy Laboratories, Ltd. |
Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo¬3.1.0 hexane derivatives as muscarinic receptor antagonists
|
BR0315784A
(pt)
*
|
2002-10-29 |
2005-09-20 |
Pharmacia & Upjohn Co Llc |
Compostos de amÈnio quaternário
|
EP1572648B1
(en)
|
2002-12-10 |
2008-07-09 |
Ranbaxy Laboratories, Ltd. |
3,6-disubstituted azabicyclo (3.1.0)-hexane derivatives as muscarinic receptor antagonists
|
AU2003301184A1
(en)
*
|
2002-12-20 |
2004-07-22 |
Dynogen Pharmaceuticals Inc |
METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING Alpha2Delta SUBUNIT CALCIUM CHANNEL MODULATORS
|
AU2002347552A1
(en)
|
2002-12-23 |
2004-07-14 |
Ranbaxy Laboratories Limited |
1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
|
ATE386738T1
(de)
|
2002-12-23 |
2008-03-15 |
Ranbaxy Lab Ltd |
Flavaxat-derivate als muscarin-rezeptor antagonisten
|
US7488748B2
(en)
|
2003-01-28 |
2009-02-10 |
Ranbaxy Laboratories Limited |
3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
BRPI0408608A
(pt)
*
|
2003-03-21 |
2006-03-07 |
Dynogen Pharmaceuticals Inc |
uso de moduladores da subunidade (alfa)2(delta) de canal de cálcio e moduladores de músculo liso para tratamento de sintoma de um distúrbio do trato urinário inferior
|
WO2004089898A1
(en)
|
2003-04-09 |
2004-10-21 |
Ranbaxy Laboratories Limited |
Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
WO2004089899A1
(en)
|
2003-04-10 |
2004-10-21 |
Ranbaxy Laboratories Limited |
Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
ATE362364T1
(de)
|
2003-04-10 |
2007-06-15 |
Ranbaxy Lab Ltd |
Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten
|
CN100436414C
(zh)
|
2003-04-11 |
2008-11-26 |
兰贝克赛实验室有限公司 |
作为毒蕈碱受体拮抗剂的氮杂双环衍生物
|
WO2004091597A2
(en)
*
|
2003-04-15 |
2004-10-28 |
Pharmacia & Upjohn Company Llc |
Method of treating irritable bowel syndrome (ibs)
|
US20050175689A1
(en)
*
|
2003-10-27 |
2005-08-11 |
Yamanouchi Pharmaceutical Co., Ltd. |
Coated fine particles containing drug for intrabuccally fast disintegrating tablet
|
US20080287680A1
(en)
*
|
2004-02-09 |
2008-11-20 |
Astellas Pharma Inc. |
Solifenacin Succinate-Containing Composition
|
WO2005077364A1
(ja)
*
|
2004-02-18 |
2005-08-25 |
Yamanouchi Pharmaceutical Co., Ltd. |
ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
|
JPWO2005087231A1
(ja)
|
2004-03-16 |
2008-01-24 |
アステラス製薬株式会社 |
ソリフェナシン含有組成物
|
CA2560080A1
(en)
*
|
2004-03-16 |
2005-09-22 |
Astellas Pharma Inc. |
Solifenacin-containing composition
|
CN1934109B
(zh)
*
|
2004-03-25 |
2010-06-23 |
安斯泰来制药株式会社 |
用于固体制剂的索非那新或其盐的组合物
|
KR20070010132A
(ko)
*
|
2004-03-25 |
2007-01-22 |
아스텔라스세이야쿠 가부시키가이샤 |
솔리페나신 또는 그의 염의 고형 제제용 조성물
|
WO2006035280A1
(en)
*
|
2004-09-27 |
2006-04-06 |
Ranbaxy Laboratories Limited |
3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases
|
US20090105221A1
(en)
*
|
2004-09-29 |
2009-04-23 |
Ranbaxy Laboratories Limited |
Muscarinic receptor antagonists
|
RU2397767C2
(ru)
*
|
2004-12-27 |
2010-08-27 |
Астеллас Фарма Инк. |
Стабильная, состоящая из частиц фармацевтическая композиция, содержащая солифенацин или его соль
|
EP1832288B1
(en)
*
|
2004-12-27 |
2012-06-20 |
Astellas Pharma Inc. |
Stable granular pharmaceutical composition of solifenacin or its salt
|
EP1852117A4
(en)
*
|
2005-02-25 |
2010-10-27 |
Astellas Pharma Inc |
PHARMACEUTICAL AGENT COMPRISING SOLIFENACIN
|
JP3701964B1
(ja)
*
|
2005-03-08 |
2005-10-05 |
アステラス製薬株式会社 |
キヌクリジン誘導体の新規な塩
|
WO2007007281A2
(en)
*
|
2005-07-11 |
2007-01-18 |
Ranbaxy Laboratories Limited |
Muscarinic receptor antagonists
|
US7815939B2
(en)
*
|
2005-07-20 |
2010-10-19 |
Astellas Pharma Inc. |
Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
|
CA2626612A1
(en)
|
2005-10-19 |
2007-04-26 |
Ranbaxy Laboratories Limited |
Pharmaceutical compositions of muscarinic receptor antagonists
|
JP2008535931A
(ja)
*
|
2005-12-21 |
2008-09-04 |
テバ ファーマシューティカル インダストリーズ リミティド |
ソリフェナシンの調製方法
|
CZ300699B6
(cs)
*
|
2006-06-21 |
2009-07-22 |
Zentiva, A. S. |
Zpusob prípravy solifenacinu
|
WO2008011462A2
(en)
*
|
2006-07-19 |
2008-01-24 |
Dr. Reddy's Laboratories Ltd. |
Process for preparing solifenacin and its salts
|
ES2298049B1
(es)
|
2006-07-21 |
2009-10-20 |
Laboratorios Almirall S.A. |
Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
|
EP2043639A2
(en)
*
|
2006-07-24 |
2009-04-08 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparing polymorphic forms of solifenacin succinate
|
US20080114029A1
(en)
*
|
2006-08-03 |
2008-05-15 |
Tamas Koltai |
Polymorphs of solifenacin intermediate
|
TW200825084A
(en)
*
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
CA2670365A1
(en)
*
|
2006-11-22 |
2008-05-29 |
Medichem S.A. |
An improved process for the synthesis of solifenacin
|
CZ300692B6
(cs)
*
|
2006-12-22 |
2009-07-15 |
Zentiva, A. S. |
Zpusob prípravy solifenacinu
|
JP2010523539A
(ja)
*
|
2007-03-30 |
2010-07-15 |
メディチェム ソシエダ アノニマ |
ソリフェナシンの改良された合成法
|
WO2009011844A1
(en)
*
|
2007-07-13 |
2009-01-22 |
Teva Pharmaceutical Industries Ltd. |
Processes for solifenacin preparation
|
KR20100040294A
(ko)
*
|
2007-07-20 |
2010-04-19 |
아스텔라스세이야쿠 가부시키가이샤 |
전립선 비대에 수반되는 하부 요로 증상의 개선용 의약 조성물
|
EP2018850A1
(en)
*
|
2007-07-24 |
2009-01-28 |
Ratiopharm GmbH |
Pharmaceutical composition comprising solifenacin or a pharmaceutically acceptable salt thereof
|
PT2216021E
(pt)
*
|
2007-11-02 |
2012-11-06 |
Astellas Pharma Inc |
Composição farmacêutica para tratar uma bexiga hiperactiva
|
US8476297B2
(en)
|
2007-12-04 |
2013-07-02 |
Amgen Inc. |
TRP-M8 receptor ligands and their use in treatments
|
WO2009087664A1
(en)
*
|
2007-12-04 |
2009-07-16 |
Cadila Healthcare Limited |
Process for preparing chemically and chirally pure solifenacin base and its salts
|
ITMI20080195A1
(it)
|
2008-02-08 |
2009-08-09 |
Dipharma Francis Srl |
Procedimento per la preparazione di solifenacin
|
EP2100599A1
(en)
|
2008-03-13 |
2009-09-16 |
Laboratorios Almirall, S.A. |
Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
|
EP2100598A1
(en)
|
2008-03-13 |
2009-09-16 |
Laboratorios Almirall, S.A. |
Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
|
ES2634421T3
(es)
|
2008-03-27 |
2017-09-27 |
Chase Pharmaceuticals Corporation |
Uso y composición para tratar la demencia
|
PL385265A1
(pl)
*
|
2008-05-23 |
2009-12-07 |
Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna |
Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
|
PL385264A1
(pl)
|
2008-05-23 |
2009-12-07 |
Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna |
Sposób wytwarzania enancjomerycznie czystej (S)-1-fenylo-1, 2, 3, 4-tetrahydroizochinoliny
|
EP3067353B1
(en)
|
2008-07-29 |
2017-11-22 |
KRKA, D.D., Novo Mesto |
A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
|
EP2181707A1
(en)
|
2008-11-04 |
2010-05-05 |
Astellas Ireland Co., Ltd. |
Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
|
CN102307579B
(zh)
|
2009-02-04 |
2013-10-16 |
安斯泰来制药株式会社 |
经口给药用医药组合物
|
ES2753979T3
(es)
*
|
2009-03-09 |
2020-04-15 |
Megafine Pharma P Ltd |
Un nuevo método para la preparación de solifenacina y nuevo intermedio de la misma
|
US20100273825A1
(en)
*
|
2009-03-30 |
2010-10-28 |
Astellas Pharma Inc. |
Solid pharmaceutical composition containing solifenacin amorphous form
|
WO2011048607A1
(en)
*
|
2009-09-25 |
2011-04-28 |
Cadila Healthcare Limited |
Processes for the preparation of solifenacin or a salt thereof
|
PL234208B1
(pl)
|
2010-01-18 |
2020-01-31 |
Zakl Farmaceutyczne Polpharma Spolka Akcyjna |
Sposób wytwarzania bursztynianu solifenacyny
|
ES2604705T3
(es)
|
2010-03-31 |
2017-03-08 |
Ono Pharmaceutical Co., Ltd. |
Agente preventivo y/o remedio para el síndrome mano-pie
|
US8748433B2
(en)
|
2010-04-30 |
2014-06-10 |
Merck Sharp & Dohme Corp. |
β3 adrenergic receptor agonists
|
US9918970B2
(en)
|
2010-05-19 |
2018-03-20 |
Astellas Pharma Inc. |
Pharmaceutical composition comprising solifenacin
|
US8772491B2
(en)
|
2010-06-28 |
2014-07-08 |
Aurobindo Pharma Ltd |
Process for the preparation of solifenacin succinate
|
EP2590973B1
(en)
|
2010-07-05 |
2016-08-31 |
Crystal Pharma, S.A.U. |
Solifenacin salts
|
CA2817336A1
(en)
|
2010-11-11 |
2012-05-18 |
Hexal Ag |
Crystalline solifenacin succinate
|
EP2510928A1
(en)
|
2011-04-15 |
2012-10-17 |
Almirall, S.A. |
Aclidinium for use in improving the quality of sleep in respiratory patients
|
CA2835277A1
(en)
|
2011-05-10 |
2012-11-15 |
Theravida, Inc. |
Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
|
JP2014520126A
(ja)
|
2011-06-22 |
2014-08-21 |
イソケム |
ソリフェナシンおよびその塩の製造方法
|
KR101365849B1
(ko)
|
2012-03-28 |
2014-02-24 |
경동제약 주식회사 |
솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체
|
JP2015521635A
(ja)
*
|
2012-07-02 |
2015-07-30 |
ファーマシェン エス.エー. |
ソリフェナシン又はその塩の調製方法
|
US20150306090A1
(en)
|
2012-08-31 |
2015-10-29 |
Astellas Pharma Inc. |
Orally administered medical composition
|
AU2013312749B2
(en)
|
2012-09-05 |
2018-01-18 |
Chase Pharmaceuticals Corporation |
Anticholinergic neuroprotective composition and methods
|
CN103787969B
(zh)
|
2012-10-30 |
2016-07-06 |
上海京新生物医药有限公司 |
一种(1s)-1-苯基-3,4-二氢-2(1h)-异喹啉甲酸酯的制备方法
|
ES2663878T3
(es)
*
|
2012-12-06 |
2018-04-17 |
Chiesi Farmaceutici S.P.A. |
Compuestos que tienen actividad antagonista del receptor muscarínico y actividad agonista del receptor beta-2 adrenérgico
|
EP2778167A1
(en)
|
2013-03-11 |
2014-09-17 |
Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi |
Stable pharmaceutical composition comprising amorphous solifenacin or its pharmaceutically acceptable salt
|
JP6218940B2
(ja)
*
|
2013-07-13 |
2017-10-25 |
ベイジン エフエスウェルカム テクノロジー ディベロップメント カンパニー リミテッド |
キニン系化合物、その光学異性体及びその製造方法と医薬用途
|
CA2944714C
(en)
|
2014-05-06 |
2023-05-16 |
Anthony G. Visco |
Methods of treating or preventing preterm labor
|
CN104592221A
(zh)
*
|
2015-01-26 |
2015-05-06 |
中山奕安泰医药科技有限公司 |
一种合成索非那新的工艺
|
KR20160146428A
(ko)
|
2015-06-12 |
2016-12-21 |
한미정밀화학주식회사 |
솔리페나신 또는 그의 약학적으로 허용되는 염과 락토즈를 포함하는 안정한 무정형 솔리페나신 약학 조성물 및 그의 제조방법
|
KR102148414B1
(ko)
|
2017-05-15 |
2020-08-26 |
주식회사 서울제약 |
솔리페나신을 유효성분으로 하는 구강붕해필름
|
WO2019118528A1
(en)
|
2017-12-12 |
2019-06-20 |
Arkuda Therapeutics |
Progranulin modulators and methods of using the same
|
CA3139561A1
(en)
|
2019-06-12 |
2020-12-17 |
Arkuda Therapeutics |
Progranulin modulators and methods of using the same
|
CN113200979A
(zh)
*
|
2021-04-13 |
2021-08-03 |
上海予君生物科技发展有限公司 |
一种琥珀酸索非那新的合成工艺
|